Alphatec Holdings Inc: (NASD: ATEC)
$1.91
-0.04 (-2.05%)
Volume 83,237
May 22 04:00 PM ET
Zacks Rank: 2-Buy 
| #2 |
Overview Quote
Stock Activity
| Day Low - High | 1.90 - 1.96 |
| 52wk Low - High | 1.41 - 2.40 |
| Previous Close | 1.95 |
| Avg. Volume | 252,417 |
| Industry | MED/DENTAL-SUPP |
| Market Cap | 188.57 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.74 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.04 |
| Quarterly Earnings ESP |
100.00% |
Premium research
Zacks Rank
|
 2 |
Zacks Recommendation
|
Underperform |
Zacks Industry Rank
|
119 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.04 |
| Current Quarter Estimate | -0.01 |
| Most Accurate Estimate | 0.00 |
| Earnings ESP |
100.00% |
| Next Earnings Report Date | 08-06-2013 |
| EPS Last Year | -0.04 |
| Expected Earnings Growth | NA |
Company Description
Alphatec is a medical device company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. Alphatec's principal product offering is primarily focused on the estimated U.S. spine fusion market through its wholly-owned subsidiary, Alphatec Spine, Inc., and includes a variety of spinal implant products and systems comprised of components such as spine screws, spinal spacers, and plates that offer multiple solutions to address patients' needs. In addition to Alphatec's U.S. presence, it also participates in the Japanese spine fusion and orthopedic trauma markets through its subsidiary, Alphatec Pacific, Inc. Its mission is to be a value based leader in the spinal market by providing unmatched service to and taking scientific direction from our physician customers.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.01 | -0.01 | -0.04 | 0.00 |
| Number of Estimates | 2 | 2 | 3 | 2 |
| Low Estimate | -0.03 | -0.03 | -0.09 | -0.03 |
| High Estimate | 0.00 | 0.01 | -0.02 | NA |
| Year Ago EPS | -0.01 | 0.01 | -0.01 | -0.04 |
| EPS Growth | -50.00% | -200.00% | -333.33% | 88.46% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ALPHATEC HLDGS | ATEC | 1.95 | |
|
| LUXOTTICA ADR | LUX | 53.97 | |
|
| CONMED CORP | CNMD | 33.24 | |
|
| COOPER COS | COO | 110.99 | |
|
| MWI VET SUPPLY | MWIV | 120.38 | |
|
| STERIS CORP | STE | 45.99 | |
|
| WEST PHARM SVC | WST | 68.41 | |
|
| ALIGN TECH INC | ALGN | 38.16 | |
|
| BARD C R INC | BCR | 106.71 | |
|
| BECTON DICKINSO | BDX | 101.01 | |
|
Sector:Medical>> Industry:MED/DENTAL-SUPP
COMPARE TICKER vs. Its Peers
Financials
| EPS TTM | -0.04 |
| Sales | 196 |
| Net Income | -17 |
| Price/Earnings | NA |
| Price/Book | 0.79 |
| Price/Cash Flow | 8.05 |
| Price/Sales | 0.95 |
News
Alphatec Spine to Present at the Jefferies Global Healthcare Conference - Globenewswire
May 21, 2013
Alphatec reports higher Q1 net loss, provides outlook for 2013 - Datamonitor
May 10, 2013
Alphatec Spine to Host Technology Day on June 6, 2013 in New York City - Globenewswire
May 9, 2013
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Alphatec Holdings, Inc. - Pr Newswire
May 9, 2013
Alphatec Spine to Present at the Bank of America Merrill Lynch 2013 Health Care Conference - Globenewswire
May 7, 2013
Alphatec Holdings, Inc.Corporate Event Announcement Notice - Wall Street Horizon
May 1, 2013
Alphatec Holdings, Inc.Corporate Event Announcement Notice - Wall Street Horizon
Apr 30, 2013
Alphatec Reaffirms - Earningswhispers Earnings Guidance
Apr 30, 2013
Broker Recommendations
| Current ABR | 1.80 |
| ABR (Last Week) | 2.00 |
| # of recs in ABR | 5 |
| Average Target Price | 2.75 |
| Industry Rank by ABR | 119 out of 265 |
| Rank in Industry | 2 out of 29 |
